| 1 |
Pardridge WM. Brain gene therapy with Trojan horse lipid nanoparticles. Trends Mol Med 2023:S1471-4914(23)00036-9. [PMID: 36907687 DOI: 10.1016/j.molmed.2023.02.004] [Reference Citation Analysis]
|
| 2 |
Chua GL, Tan BC, Loke RYJ, He M, Chin CF, Wong BH, Kuk ACY, Ding M, Wenk MR, Guan L, Torta F, Silver DL. Mfsd2a utilizes a flippase mechanism to mediate omega-3 fatty acid lysolipid transport. Proc Natl Acad Sci U S A 2023;120:e2215290120. [PMID: 36848557 DOI: 10.1073/pnas.2215290120] [Reference Citation Analysis]
|
| 3 |
Pardridge WM. Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs. Pharm Res 2023;40:661-74. [PMID: 36829100 DOI: 10.1007/s11095-023-03484-2] [Reference Citation Analysis]
|
| 4 |
Manuel M, Tamba B, Leclere M, Mabrouk M, Schreiner T, Ciobanu R, Cristina T. Intrathecal Pseudodelivery of Drugs in the Therapy of Neurodegenerative Diseases: Rationale, Basis and Potential Applications. Pharmaceutics 2023;15:768. [DOI: 10.3390/pharmaceutics15030768] [Reference Citation Analysis]
|
| 5 |
Abballe L, Spinello Z, Antonacci C, Coppola L, Miele E, Catanzaro G, Miele E. Nanoparticles for Drug and Gene Delivery in Pediatric Brain Tumors' Cancer Stem Cells: Current Knowledge and Future Perspectives. Pharmaceutics 2023;15. [PMID: 36839827 DOI: 10.3390/pharmaceutics15020505] [Reference Citation Analysis]
|
| 6 |
Hamed R, Eyal AD, Berman E, Eyal S. In silico screening for clinical efficacy of antiseizure medications: Not all central nervous system drugs are alike. Epilepsia 2023;64:311-9. [PMID: 36478573 DOI: 10.1111/epi.17479] [Reference Citation Analysis]
|
| 7 |
Chaulagain B, Gothwal A, Lamptey RNL, Trivedi R, Mahanta AK, Layek B, Singh J. Experimental Models of In Vitro Blood-Brain Barrier for CNS Drug Delivery: An Evolutionary Perspective. Int J Mol Sci 2023;24. [PMID: 36769032 DOI: 10.3390/ijms24032710] [Reference Citation Analysis]
|
| 8 |
Pineda E, Domenech M, Hernández A, Comas S, Balaña C. Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects. Onco Targets Ther 2023;16:71-86. [PMID: 36721854 DOI: 10.2147/OTT.S366371] [Reference Citation Analysis]
|
| 9 |
Furtado J, Geraldo LH, Leser FS, Poulet M, Park H, Pibouin-Fragner L, Eichmann A, Boyé K. Netrin-1 binding to Unc5B regulates Blood-Retina Barrier integrity. bioRxiv 2023:2023. [PMID: 36711611 DOI: 10.1101/2023.01.21.525006] [Reference Citation Analysis]
|
| 10 |
Tian T, Qiao S, Tannous BA. Nanotechnology-Inspired Extracellular Vesicles Theranostics for Diagnosis and Therapy of Central Nervous System Diseases. ACS Appl Mater Interfaces 2023;15:182-99. [PMID: 35929960 DOI: 10.1021/acsami.2c07981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Nielsen SSE, Holst MR, Langthaler K, Bruun EH, Brodin B, Nielsen MS. Apicobasal transferrin receptor localization and trafficking in brain capillary endothelial cells. Fluids Barriers CNS 2023;20:2. [PMID: 36624498 DOI: 10.1186/s12987-022-00404-1] [Reference Citation Analysis]
|
| 12 |
Pardridge WM. Advanced Blood-Brain Barrier Drug Delivery. Pharmaceutics 2022;15:93. [PMID: 36678722 DOI: 10.3390/pharmaceutics15010093] [Reference Citation Analysis]
|
| 13 |
Mehkri Y, Woodford S, Pierre K, Dagra A, Hernandez J, Reza Hosseini Siyanaki M, Azab M, Lucke-Wold B. Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors. Curr Oncol 2022;29:8846-61. [PMID: 36421349 DOI: 10.3390/curroncol29110696] [Reference Citation Analysis]
|
| 14 |
Hugele A, Löffler S, Molina BH, Guillon M, Montaser AB, Auriola S, Huttunen KM. Aminopeptidase B can bioconvert L-type amino acid transporter 1 (LAT1)-utilizing amide prodrugs in the brain. Front Pharmacol 2022;13:1034964. [DOI: 10.3389/fphar.2022.1034964] [Reference Citation Analysis]
|
| 15 |
Su S, Esparza TJ, Brody DL. Selection of single domain anti-transferrin receptor antibodies for blood-brain barrier transcytosis using a neurotensin based assay and histological assessment of target engagement in a mouse model of Alzheimer's related amyloid-beta pathology. PLoS One 2022;17:e0276107. [PMID: 36256604 DOI: 10.1371/journal.pone.0276107] [Reference Citation Analysis]
|
| 16 |
Minami K, Morimoto H, Morioka H, Imakiire A, Kinoshita M, Yamamoto R, Hirato T, Sonoda H. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses. IJMS 2022;23:11724. [DOI: 10.3390/ijms231911724] [Reference Citation Analysis]
|
| 17 |
Pearce J, Hull Royal Infirmary, Hull, UK. The blood brain barrier and Lina Solomonovna Stern (Shtern). ACNR 2022;21. [DOI: 10.47795/evrj6805] [Reference Citation Analysis]
|
| 18 |
Sahin O, Thompson HP, Goodman GW, Li J, Urayama A. Mucopolysaccharidoses and the blood-brain barrier. Fluids Barriers CNS 2022;19:76. [PMID: 36117162 DOI: 10.1186/s12987-022-00373-5] [Reference Citation Analysis]
|
| 19 |
Kuznetsova DA, Gaynanova GA, Vasilieva EA, Pavlov RV, Zueva IV, Babaev VM, Kuznetsov DM, Voloshina AD, Petrov KA, Zakharova LY, Sinyashin OG. Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning. Pharmaceutics 2022;14:1950. [DOI: 10.3390/pharmaceutics14091950] [Reference Citation Analysis]
|
